February 15, 2021

Israeli Study Shows Pfizer Vaccine, Now Also in Rwanda, is 94 percent Effective


Trustworthy and indepth news stories are more important now than ever.
Support our newsroom by MAKING A CONTRIBUTION HERE

Israel’s largest healthcare provider said Sunday a study of more than half a million fully vaccinated Israelis indicated the Pfizer/biotechnologies jab gave 94 percent protection against COVID-19. It is the same vaccine now already in Rwanda.

Clalit Health Services said that in a groundbreaking project its researchers tested 600,000 subjects who had received the recommended two doses of the US-German Pfizer/BioNTech vaccine and the same number of people who had not been innoculated.

“There was a 94 percent reduction in the rate of symptomatic infection and a 92 percent decrease in the rate of serious illness compared to 600,000 similar (subjects) who were not vaccinated,” Clalit said in a Hebrew-language statement.

“Vaccine efficacy is maintained in all age groups, including those aged 70+,” it added.

Israel’s mass vaccination campaign has seen 3.8 million people receive a first dose, while 2.4 million have also received a second shot.

The country of nine million people, which is currently easing restrictions imposed during its third nationwide lockdown, is aiming to vaccinate everyone over the age of 16 by the end of March.

“The publication of preliminary results at this stage is intended to emphasise to the unvaccinated population that the vaccine is highly effective and prevents serious morbidity,” Clalit said Sunday.

It added that the study covered people who had received the second shot at least seven days before being tested, and would be expanded in future.

“With each additional week that passes, we will be able to make the assessment more accurate.”

Accuracy would improve as subjects are tested after 14 days or more from the second dose, it said.

Israel has so far relied on only the Pfizer/BioNTech vaccine, although it holds a small stock of the vaccine developed by US biotech firm Moderna.

Israel secured plentiful supplies of vaccine from Pfizer after striking a data-sharing deal with the US manufacturer.

The agreement stipulates that the Jewish state, which has one of the world’s most sophisticated medical data systems, will share real-time information with Pfizer on the vaccine‘s impact, including on progress towards herd immunity.

Clalit is the biggest of Israel’s four health service providers, which collectively provide healthcare to the entire population.

They are directly responsible for vaccinations and collecting data on their impact.

Meanwhile, Rwanda’s health ministry confirmed on Sunday that it had began vaccinating “high risk” groups like healthcare workers. Rumours had been circulating since early last week that indeed government had acquired the vaccine and that some people had gotten the jab, but strangely the official confirmation came later.

Sources also suggests it is the Pfizer/BioNTech vaccine which is in the country.

Details still not clear if these were purchased, but pointed out they were got through “international partnerships”. However, Rwanda had been scheduled to get at least 1.1m jabs from the COVAX facility, a global entity that’s helping mobilize vaccines for poor nations.

In the health ministry statement on Sunday, it said it was beginning with high risk groups, but that the “wider roll-out” will be done later month with the COVAX supplies and others from the African Union program.

Adapted from agencies

We can't do quality journalism without your support

Perhaps it goes without saying — but producing quality journalism isn't cheap. At a time when newsroom resources and revenue are declining, The Chronicles remains committed to "Serving Your Right To Know The Truth". Stand with us as we document Rwanda's remarkable journey for you and the future generation. Do you value our journalism? We can't do it without you. Show us with your support by CONTRIBUTING HERE.
Email your news TIPS to info@chronicles.rw or WhatsApp +250788351327.
You can also find us on Signal

Leave a Reply

Your email address will not be published. Required fields are marked *